Cefoselis sulfate | CAS#122841-12-7 (sulfate)

MedKoo Cat#: 315216 | Name: Cefoselis sulfate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefoselis sulfate is a stable cephalosporin for BETA-lactamase. The drug shows antimicrobial activity for a wide range of bacteria including Pseudomonas.

Chemical Structure

Cefoselis sulfate

CAS#122841-12-7 (sulfate)

Theoretical Analysis

MedKoo Cat#: 315216

Name: Cefoselis sulfate

CAS#: 122841-12-7 (sulfate)

Chemical Formula: C19H24N8O10S3

Exact Mass: 0.0000

Molecular Weight: 620.64

Elemental Analysis: C, 36.77; H, 3.90; N, 18.05; O, 25.78; S, 15.50

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 350.00	2 Weeks
50mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

122841-10-5 (free base) 122841-12-7 (sulfate)

Synonym

Cefoselis sulfate; Cefoselis (sulfate); Winsef; FK 037; FK037; FK-037;

IUPAC/Chemical Name

(6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((2-(2-hydroxyethyl)-3-imino-2,3-dihydro-1H-pyrazol-1-yl)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid compound with sulfuric acid (1:1)

InChi Key

LZOLCSVRFKCSEM-ZQCAECPKSA-N

InChi Code

InChI=1S/C19H22N8O6S2.H2O4S/c1-33-24-12(10-8-35-19(21)22-10)15(29)23-13-16(30)27-14(18(31)32)9(7-34-17(13)27)6-25-3-2-11(20)26(25)4-5-28;1-5(2,3)4/h2-3,8,13,17,20,28H,4-7H2,1H3,(H2,21,22)(H,23,29)(H,31,32);(H2,1,2,3,4)/b20-11?,24-12-;/t13-,17-;/m1./s1

SMILES Code

O=C(C(N12)=C(CN3N(CCO)C(C=C3)=N)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)O.O=S(O)(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO.

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 620.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ohtaki K, Matsubara K, Fujimaru S, Shimizu K, Awaya T, Suno M, Chiba K, Hayase N, Shiono H. Cefoselis, a beta-lactam antibiotic, easily penetrates the blood-brain barrier and causes seizure independently by glutamate release. J Neural Transm (Vienna). 2004 Dec;111(12):1523-35. doi: 10.1007/s00702-004-0177-0. Epub 2004 Jul 7. PMID: 15565489. 2: Zheng Y, Wang N, Wang S, Pan B, Yang B, Zhang J, Wang X, Wang Z. Cefoselis enhances breast cancer chemosensitivity by directly targeting GRP78/LRP5 signalling of cancer stem cells. Clin Transl Med. 2023 Feb;13(2):e1119. doi: 10.1002/ctm2.1119. PMID: 36808887; PMCID: PMC9939292. 3: Zalewski P, Skibiński R, Talaczyńska A, Paczkowska M, Garbacki P, Cielecka- Piontek J. Stability studies of cefoselis sulfate in the solid state. J Pharm Biomed Anal. 2015 Oct 10;114:222-6. doi: 10.1016/j.jpba.2015.05.033. Epub 2015 Jun 1. PMID: 26073113. 4: Cheng JW, Su JR, Xiao M, Yu SY, Zhang G, Zhang JJ, Yang Y, Duan SM, Kudinha T, Yang QW, Xu YC. In vitro Activity of a New Fourth-Generation Cephalosporin, Cefoselis, Against Clinically Important Bacterial Pathogens in China. Front Microbiol. 2020 Feb 28;11:180. doi: 10.3389/fmicb.2020.00180. PMID: 32184764; PMCID: PMC7058541. 5: Li X, Jia P, Zhu Y, Xu Y, Yu Y, Lv Y, Wang M, Sun Z, Lin J, Li Y, Zheng B, Hu F, Guo Y, Chen Z, Li H, Zhang G, Zhang J, Kang W, Duan S, Wang T, Jing R, Yang Q. Establishment of epidemiological cut-off values for cefoselis, a new fourth- generation cephalosporin, against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis and Pseudomonas aeruginosa. J Antimicrob Chemother. 2021 Sep 15;76(10):2593-2599. doi: 10.1093/jac/dkab216. PMID: 34215878. 6: Yamazaki S, Mochizuki Y, Terai T, Sugimoto M, Uchida I, Matsuoka N, Mutoh S. Intracerebroventricular injection of the antibiotic cefoselis produces convulsion in mice via inhibition of GABA receptors. Pharmacol Biochem Behav. 2002 Dec;74(1):53-9. doi: 10.1016/s0091-3057(02)00947-4. PMID: 12376152. 7: Chen J, Liu Y, Jia W, Xu X, Sun G, Wang T, Li J, Zhang G, Jing R, Sun H, Xu Y, Liu Y. In Vitro Activities of Aztreonam-Avibactam, Eravacycline, Cefoselis, and Other Comparators against Clinical Enterobacterales Isolates: a Multicenter Study in China, 2019. Microbiol Spectr. 2023 Jun 15;11(3):e0487322. doi: 10.1128/spectrum.04873-22. Epub 2023 May 15. PMID: 37184411; PMCID: PMC10269566. 8: Liu YB, Lv XJ, Yu RJ, Qiu HM, Bai JL, Jiang N, Lin JM, Liu YJ, Yan HY, Song SD, He P, Guo DY, Li XS. Multicenter, double-blind, randomized clinical trial of parenterally administered Cefoselis versus Cefepime for the treatment of acute bacterial infections. Eur Rev Med Pharmacol Sci. 2014;18(14):2006-12. PMID: 25027339. 9: Sugimoto M, Fukami S, Kayakiri H, Yamazaki S, Matsuoka N, Uchida I, Mashimo T. The beta-lactam antibiotics, penicillin-G and cefoselis have different mechanisms and sites of action at GABA(A) receptors. Br J Pharmacol. 2002 Jan;135(2):427-32. doi: 10.1038/sj.bjp.0704496. PMID: 11815378; PMCID: PMC1573156. 10: Giamarellos-Bourboulis EJ, Grecka P, Tsitsika A, Tympanidou C, Giamarellou H. In-vitro activity of FK 037 (Cefoselis), a novel 4(th) generation cephalosporin, compared to cefepime and cefpirome on nosocomial staphylococci and gram-negative isolates. Diagn Microbiol Infect Dis. 2000 Mar;36(3):185-91. doi: 10.1016/s0732-8893(99)00131-5. PMID: 10729661. 11: Chimura T, Hirayama T, Morisaki N, Murayama K, Sato F, Akatsuka K, Numazaki M, Igarashi Y. [Clinical effects of cefoselis (CFSL) on infections in obstetric and gynecologic field and prevention of postoperative infections]. Jpn J Antibiot. 2000 Nov;53(11):637-41. Japanese. PMID: 11211699. 12: Nagata M, Yasuhara M. Effect of experimental renal failure on the pharmacodynamics of cefoselis-induced seizures in rats. Biol Pharm Bull. 2001 Sep;24(9):1049-52. doi: 10.1248/bpb.24.1049. PMID: 11558567. 13: King A, Bethune L, Phillips I. The Comparative In Vitro Activity of FK-037 (Cefoselis), a New Broad-Spectrum Cephalosporin. Clin Microbiol Infect. 1995 Sep;1(1):13-17. doi: 10.1111/j.1469-0691.1995.tb00018.x. PMID: 11866715. 14: Liu HB, Liu F, Kong QT, Shen YN, Lv GX, Liu WD, Sang H. Successful Treatment of Refractory Majocchi's Granuloma with Voriconazole and Review of Published Literature. Mycopathologia. 2015 Oct;180(3-4):237-43. doi: 10.1007/s11046-015-9902-5. Epub 2015 Jun 5. PMID: 26045285. 15: Hanaki H, Hiramatsu K. [Combination effect of teicoplanin and various antibiotics against hetero-VRSA and VRSA]. Kansenshogaku Zasshi. 1999 Oct;73(10):1048-53. Japanese. doi: 10.11150/kansenshogakuzasshi1970.73.1048. PMID: 10565121. 16: Wise R. Tissue penetration of the fourth generation parenteral cephalosporins. J Chemother. 1996 Feb;8 Suppl 2:63-70. PMID: 8738848. 17: Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V. beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem. 2000 Jan 21;275(3):1699-707. doi: 10.1074/jbc.275.3.1699. PMID: 10636865. 18: Watanabe NA. Newer antipseudomonal cephalosporins. J Chemother. 1996 Feb;8 Suppl 2:48-56. PMID: 8738846. 19: Chang KY, Kim SH, Nam G, Seo JH, Kim JH, Ha DC. Synthesis and structure- activity relationships of quaternary ammonium cephalosporins with 3-pyrazolylpyridinium derivatives. Bioorg Med Chem Lett. 2000 Jun 5;10(11):1211-4. doi: 10.1016/s0960-894x(00)00203-1. PMID: 10866383. 20: Sugimoto M, Uchida I, Mashimo T, Yamazaki S, Hatano K, Ikeda F, Mochizuki Y, Terai T, Matsuoka N. Evidence for the involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins. Neuropharmacology. 2003 Sep;45(3):304-14. doi: 10.1016/s0028-3908(03)00188-6. PMID: 12871648.